metformin has been researched along with Cancer of the Uterus in 7 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 8.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 4.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "Metformin treatment reduces the risk of cancer in type 2 diabetes patients." | 1.46 | Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes. ( Junik, R; Muszyńska-Ogłaza, A; Olejniczak, H; Polaszewska-Muszyńska, M; Zarzycka-Lindner, G, 2017) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes." | 1.39 | Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. ( Attias-Geva, Z; Bruchim, I; Fishman, A; Friedman, Y; Sarfstein, R; Werner, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muszyńska-Ogłaza, A | 1 |
| Zarzycka-Lindner, G | 1 |
| Olejniczak, H | 1 |
| Polaszewska-Muszyńska, M | 1 |
| Junik, R | 1 |
| Clement, NS | 1 |
| Oliver, TR | 1 |
| Shiwani, H | 1 |
| Sanner, JR | 1 |
| Mulvaney, CA | 1 |
| Atiomo, W | 1 |
| Kitson, SJ | 1 |
| Maskell, Z | 1 |
| Sivalingam, VN | 1 |
| Allen, JL | 1 |
| Ali, S | 1 |
| Burns, S | 1 |
| Gilmour, K | 1 |
| Latheef, R | 1 |
| Slade, RJ | 1 |
| Pemberton, PW | 1 |
| Shaw, J | 1 |
| Ryder, WD | 1 |
| Kitchener, HC | 1 |
| Crosbie, EJ | 1 |
| Sarfstein, R | 1 |
| Friedman, Y | 1 |
| Attias-Geva, Z | 1 |
| Fishman, A | 1 |
| Bruchim, I | 1 |
| Werner, H | 1 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Zhang, L | 1 |
| Liao, Q | 1 |
| Gowri, V | 1 |
| Jain, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)[NCT03257228] | 24 participants (Actual) | Observational | 2014-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Cancer of the Uterus
| Article | Year |
|---|---|
Metformin for endometrial hyperplasia.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease Progression; Endometrial Hyperplasia; Female; | 2017 |
1 trial available for metformin and Cancer of the Uterus
| Article | Year |
|---|---|
PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Proliferation; Female; Humans; Hypoglycemic | 2019 |
5 other studies available for metformin and Cancer of the Uterus
| Article | Year |
|---|---|
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfor | 2017 |
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Topics: Adenylate Kinase; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S | 2013 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Effects of testosterone and metformin on glucose metabolism in endometrium.
Topics: Adult; Cells, Cultured; Endometriosis; Endometrium; Epithelial Cells; Female; Follicular Phase; Gene | 2010 |
Investigating infertility.
Topics: Antineoplastic Agents; Dermoid Cyst; Female; Humans; Infertility, Female; Medical History Taking; Me | 2009 |